CN114377143A - 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 - Google Patents

用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 Download PDF

Info

Publication number
CN114377143A
CN114377143A CN202111299877.1A CN202111299877A CN114377143A CN 114377143 A CN114377143 A CN 114377143A CN 202111299877 A CN202111299877 A CN 202111299877A CN 114377143 A CN114377143 A CN 114377143A
Authority
CN
China
Prior art keywords
carrier molecule
carrier
cells
dextran backbone
receptor substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111299877.1A
Other languages
English (en)
Chinese (zh)
Inventor
F.科普
M.布卢
W.梅茨
L.施勒辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Candler Health 414 LLC
Ohio State Innovation Foundation
Original Assignee
Candler Health 414 LLC
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Candler Health 414 LLC, Ohio State Innovation Foundation filed Critical Candler Health 414 LLC
Publication of CN114377143A publication Critical patent/CN114377143A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
CN202111299877.1A 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 Pending CN114377143A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361857232P 2013-07-22 2013-07-22
US61/857232 2013-07-22
US201361879649P 2013-09-18 2013-09-18
US61/879649 2013-09-18
PCT/US2014/047708 WO2015013341A1 (en) 2013-07-22 2014-07-22 Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
CN201480051858.9A CN105764529A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480051858.9A Division CN105764529A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒

Publications (1)

Publication Number Publication Date
CN114377143A true CN114377143A (zh) 2022-04-22

Family

ID=51352773

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111299877.1A Pending CN114377143A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
CN201480051858.9A Pending CN105764529A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480051858.9A Pending CN105764529A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒

Country Status (11)

Country Link
US (2) US20150023876A1 (https=)
EP (1) EP3024493A1 (https=)
JP (1) JP6607854B2 (https=)
KR (2) KR20210095972A (https=)
CN (2) CN114377143A (https=)
AU (3) AU2014293198A1 (https=)
CA (1) CA2918782C (https=)
HK (1) HK1225623A1 (https=)
IL (1) IL243645B (https=)
WO (1) WO2015013341A1 (https=)
ZA (1) ZA201600453B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
CN108348619A (zh) * 2015-09-25 2018-07-31 瑟日尼有限责任公司 Sn-117m标记的甘露糖偶联的葡聚糖胺
WO2018067751A1 (en) * 2016-10-04 2018-04-12 Navidea Biopharmaceuticals, Inc. Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
EP3522899A4 (en) * 2016-10-07 2020-05-06 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
MX2019004029A (es) 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
US11286172B2 (en) 2017-02-24 2022-03-29 BWXT Isotope Technology Group, Inc. Metal-molybdate and method for making the same
US11363709B2 (en) 2017-02-24 2022-06-14 BWXT Isotope Technology Group, Inc. Irradiation targets for the production of radioisotopes
CA3064277A1 (en) * 2017-05-19 2018-11-22 Navidea Biopharmaceuticals, Inc. Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS
CA3127487A1 (en) * 2019-01-25 2020-07-30 Navidea Biopharmaceuticals, Inc. Compositions and methods for assessing macrophage mediated pathology
GB201902810D0 (en) * 2019-03-01 2019-04-17 Vidya Holdings Ltd Disposition of reagents in assay device
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
US20210145989A1 (en) * 2019-09-30 2021-05-20 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
GB201915222D0 (en) * 2019-10-21 2019-12-04 Univ Court Univ Of Glasgow Diagnostic and prognostic biomarkers of disease remission in rheumatoid arthritis
EP4076540A4 (en) 2020-07-08 2024-02-21 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
WO2022157373A1 (en) * 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
CN113899909A (zh) * 2021-09-30 2022-01-07 上海交通大学医学院附属瑞金医院 可溶性cd206在制备抗中性粒细胞胞浆抗体相关性血管炎诊断试剂盒中的应用
EP4472643A1 (en) 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
JP2025517414A (ja) 2022-05-20 2025-06-05 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 分解性リンカーを介して新規ビスホスホネート薬物ペイロードを担持するｃｄ２０６標的化薬物送達ビヒクル
WO2024076988A2 (en) 2022-10-03 2024-04-11 Navidea Biopharmaceuticals, Inc. Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers
WO2024178142A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
CN119592679B (zh) * 2024-11-25 2025-06-24 中日友好医院(中日友好临床医学研究所) 一种用于评估皮肌炎/抗合成酶综合征相关间质性肺疾病严重程度及预后的新型标记物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004085929A (ja) * 2002-08-27 2004-03-18 Fuji Photo Optical Co Ltd 光学素子
US20090311182A1 (en) * 2004-03-31 2009-12-17 Dong Wang Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
SG166016A1 (en) * 2009-04-16 2010-11-29 Fan Wang Yiang Financial education planner and method of using thereof
US9101674B2 (en) * 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US20130330274A1 (en) * 2012-05-22 2013-12-12 University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for detecting and treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
左大明, 陈政良: "巨噬细胞甘露糖受体的结构与功能", 免疫学杂志, vol. 20, no. 3, 30 June 2004 (2004-06-30), pages 15 - 17 *

Also Published As

Publication number Publication date
JP6607854B2 (ja) 2019-11-20
CA2918782C (en) 2024-03-12
ZA201600453B (en) 2019-09-25
US20150023876A1 (en) 2015-01-22
AU2022205225A1 (en) 2022-08-04
KR20210095972A (ko) 2021-08-03
KR20160055791A (ko) 2016-05-18
IL243645A0 (en) 2016-02-29
AU2014293198A1 (en) 2016-02-04
US20220016272A1 (en) 2022-01-20
AU2020200293A1 (en) 2020-02-06
CA2918782A1 (en) 2015-01-29
WO2015013341A1 (en) 2015-01-29
EP3024493A1 (en) 2016-06-01
HK1225623A1 (zh) 2017-09-15
JP2016527252A (ja) 2016-09-08
AU2020200293B2 (en) 2022-04-21
IL243645B (en) 2019-12-31
CN105764529A (zh) 2016-07-13
KR102284389B1 (ko) 2021-08-03

Similar Documents

Publication Publication Date Title
AU2020200293B2 (en) Compositions, methods and kits for diagnosing and treating CD206 expressing cell-related disorders
US12097264B2 (en) Methods and compositions for theranostic nanoparticles
JP7455510B2 (ja) 悪性脳腫瘍における標的化粒子の浸透、分布および応答のための組成物及び方法
Lesniak et al. Evaluation of PSMA-targeted PAMAM dendrimer nanoparticles in a murine model of prostate cancer
ES2787099T3 (es) Fucoidanos como ligandos para el diagnóstico de patologías degenerativas
CA2955438C (en) DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2016118188A1 (en) Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
Kang et al. 64Cu-Labeled tetraiodothyroacetic acid-conjugated liposomes for PET imaging of tumor angiogenesis
JP2023538134A (ja) 腫瘍関連マクロファージを標的とするための組成物及び方法
Chen et al. Multifunctional gold nanocomposites designed for targeted CT/MR/optical trimodal imaging of human non-small cell lung cancer cells
Kong et al. Multifunctional Probe Based on “Chemical Antibody–Aptamer” for Noninvasive Detection of PD-L1 Expression in Cancer
US20210338848A1 (en) Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
HK40073647A (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
US20220280659A1 (en) Targeted Nanoparticles of Well-Defined and Reproducible Sizes
CA3022354C (en) Methods and compositions for theranostic nanoparticles
Singh et al. Nanocarriers in Early Diagnosis of Cancer
Buckway Image-guided therapeutic delivery to solid tumors with HPMA copolymers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073647

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220422

WD01 Invention patent application deemed withdrawn after publication